Akoya BioSciencesAKYA
AKYA
About: Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
Employees: 205
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
7,400% more call options, than puts
Call options by funds: $75K | Put options by funds: $1K
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
18% more capital invested
Capital invested by funds: $27.8M [Q4 2024] → $32.8M (+$5.05M) [Q1 2025]
5% more funds holding
Funds holding: 61 [Q4 2024] → 64 (+3) [Q1 2025]
0.75% more ownership
Funds ownership: 24.49% [Q4 2024] → 25.24% (+0.75%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1.08
12%
downside
Avg. target
$1.51
23%
upside
High target
$1.80
46%
upside
3 analyst ratings
0 positive
0%
3 neutral
100%
0 negative
0%
Canaccord Genuity Kyle Mikson | 12%downside $1.08 | Hold Maintained | 19 May 2025 |
Piper Sandler David Westenberg | 34%upside $1.65 | Neutral Maintained | 14 Apr 2025 |
Stephens & Co. Mason Carrico | 46%upside $1.80 | Equal-Weight Downgraded | 25 Mar 2025 |
Financial journalist opinion
Neutral
PRNewsWire
3 weeks ago
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ: AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya.
Negative
Zacks Investment Research
1 month ago
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Akoya Biosciences Reports First Quarter 2025 Financial Results
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025.
Neutral
Business Wire
1 month ago
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to.
Negative
Zacks Investment Research
1 month ago
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the “Amended Merger Agreement”) related to its proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA): “Quanterix's decision to press on with the Merger in the face.
Neutral
Business Wire
1 month ago
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya s.
Neutral
GlobeNewsWire
1 month ago
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer.
Neutral
GlobeNewsWire
1 month ago
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community.
Neutral
GlobeNewsWire
1 month ago
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing together Singapore's public healthcare and research institutions in the translational cancer research ecosystem, comprising the National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), National University Hospital (NUH), National University of Singapore (NUS), Singapore General Hospital (SGH) and the Agency for Science, Technology and Research (A*STAR). The partnership between Akoya Biosciences and STCC will leverage Akoya Biosciences' PhenoCode™ Discovery IO60 Panel in the SUPER study to immunophenotype matched pairs of immuno-oncology exceptional responders and hyper-progressors through advanced spatial multiplexed analyses.
Charts implemented using Lightweight Charts™